

Excellence in Care:  
New Drugs Released in 2007 and 2008

Renee Acosta, RPh



INDEPENDENT STUDY

Health Professions Institute  
for Continuing Education

Austin Community College



The Austin Community College  
Health Professions Institute, Continuing Education  
5930 Middle Fiskville Road, Austin, TX 78752

**INDEPENDENT STUDY: Excellence in Care: New Drugs Released in 2007 and 2008**

**Description and Purpose:** Renee Acosta, RPh, appears with Elizabeth Huss RN, BSN, coordinator with the Health Professions Institute of Austin Community College, to discuss new medications released in 2007 and 2008 and includes information on mechanism of action, classification, indication, dosing/administration, and special considerations. Ms. Acosta is an instructor for the School of Pharmacy at the University of Texas at Austin and developer of the Pharmacy Technician Program at Austin Community College as well as a published author.

The purpose of this activity is to enrich the participant's contribution to quality healthcare and the pursuit of professional career goals by providing updated information on the use, interaction concerns, and precautions needed regarding new medications approved by the FDA and released in 2007 and 2008.

This offering is a self-paced learning activity developed to meet the individual needs of nurses, social workers, and emergency medical services personnel requiring continuing education for relicensure.

**Goals and Objectives:** Upon completion of this activity, the student will be able to:

1. Identify two (2) classifications in which the new drugs released in 2007 and 2008 address.
2. Identify the required warning (by the FDA) to be placed on pharmaceutical labels when there is something important or outstanding about a medication (particularly a side effect).
3. List two (2) new topical drugs available for the treatment of pain.
4. Describe three (3) new drugs released in 2007 and 2008 including their mechanism of action, route of administration, and any special considerations.
5. Discuss the future of pharmaceutical development and its relationship to cellular markers.
6. Discuss the healthcare professionals responsibility in staying current with new pharmaceuticals released each year.

**Requirements for Successful Completion:** The packet you have received contains a pre-test, DVD, post-test and a program evaluation. To successfully complete this activity and earn continuing education the participant must:

1. Complete the pre-test
2. View the DVD
3. Complete the post-test (score an 80 or more)
4. And, complete the evaluation

NOTE: Following the viewing of the DVD and completing the accompanying documents, questions may be addressed by contacting Elizabeth Huss @ 512-223-7271 or eahuss@austincc.edu

Submit all of the documents (pre/post-test, evaluation) along with your completed Registration Form (check or credit card), and payment to:

**Austin Community College  
Health Professions Institute  
Attn: Online Nursing Videos  
5930 Middle Fiskville Rd.  
Austin, TX 78752  
Fax: 512-223-7030**

Within two business weeks from receipt of your material at ACC, your certificate of completion will be available (to be mailed, fax, or picked up at the above address ... your choice).

Upon successful completion participants will be awarded a certificate of successful completion worth 2.0 contact hours.

Austin Community College is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Contact hours for programs applicable to social work are approved for CEU's by the Texas State Board of Social Worker Examiners. This program is worth 2.0 contact hours or 0.2 continuing education units (CEU's).

Continuing education for Emergency Medical Personnel is approved by the Texas Department of State Health Services. This program is worth 2.0 TDH (P) contact hours.

**Disclosure to Attendees:** The presenters and planning committee members for this offering have completed Conflict of Interest forms and it has been determined that no conflict of interest exists or has been identified in relation to this offering.

**Commercial Support:** This offering has not received any commercial support.

**Non-endorsement of products:** The discussion of generic or brand name items or medications does not constitute endorsement by the American Nurses Credential Center's Commission on Accreditation (ANCC), the Texas Nurses Association (TNA) or Austin Community College.

**Off-Label Use:** Off-label use of medications refers to the prescribing of medications to treat a condition for which the medication has not been approved by the Food and Drug Administration. Medications presented in this activity will only be discussed in the context of their Federal Drug Administration (FDA) approval.

**Printed Name:**

**Date:**

**Instructions:** Complete this pre-test PRIOR to watching the video. Choose the best answer by circling the letter corresponding to your choice. Submit this pre-test only with your post-test, completed evaluation, completed registration, and payment to:

**Austin Community College  
Health Professions Institute  
Attn: Online Nursing Videos  
5930 Middle Fiskville Rd.  
Austin, TX 78752  
Fax: 512-223-7030**

**Pre-Test: New Drugs Released in 2007 and 2008**

1. Healthcare professionals have a responsibility to:
  - a. Stay current with regard to new drugs approved each year
  - b. Learn about those drugs they frequently work with
  - c. Know where to find information pertaining to drugs and drug therapy
  - d. All of the above
  
2. All of the following are true about Aliskiren (Tekturna) EXCEPT:
  - a. It is indicated for the treatment of hypertension
  - b. Dosing is usually 150 mg daily
  - c. Must be given consistently with regard to meals
  - d. Must be given without food
  
3. When there is something important about a medication (particularly a side effect), the FDA requires a warning on the label up-front. What is this warning called?
  - a. Black box warning
  - b. WARNING:
  - c. CAUTION:
  - d. Red Alert
  
4. Which of the following drug(s) has a pending FDA approval for the treatment of vasomotor symptoms associated with menopause?
  - a. Arformoterol (Brovana)
  - b. Desvenlafaxine (Pristiq)
  - c. Ambrisentan (Letairis)
  - d. Diclofenac epolamine topical patch 1.3% (Flector)

Pre-test Drugs of 2007 and 2008 Con't

5. This antimicrobial / bactericidal IV medication used to treat severe infections requires adjusting the dosage for the creatinine clearance.

- a. Doripenem (Doribox)
- b. Eculizumab (Soliris)
- c. Diclofenac epolamine topical patch 1.3% (Flector)
- d. Diclofenac sodium (Voltaren gel 1%)

6. All of the following are true concerning the drug Eculizumab (Soliris) EXCEPT:

- a. It decreases the destruction of red blood cells
- b. It is administered IV
- c. It is the first drug approved for PNH (paroxysmal nocturnal hemoglobinuria)
- d. It is given orally

7. Of the following drug(s), which comes with a recommendation for the meningococcal vaccine at least 2 weeks prior to receiving the first dose because of an increased risk for meningococcal infections?

- a. Fesoterodine (Toviaz)
- b. Ixabepilone (Ixempra)
- c. Eculizumab (Soliris)
- d. Methylnaltrexone bromide (Relistor)

8. Which of the following drug(s) is administered via deep subcutaneous injection and is given for the long-term treatment of acromegalic clients?

- a. Lapatinib (Tykerb)
- b. Levocetirizine (Xyzal)
- c. Lubiprostone (Amitiza)
- d. Lanreotide (Somatuline Depot)

9. Which of the following drug(s) is given for advanced or metastatic breast cancer tumors that over-express HER2 and in combination with capecitabine?

- a. Lapatinib (Tykerb)
- b. Levocetirizine (Xyzal)
- c. Lubiprostone (Amitiza)
- d. Lanreotide (Somatuline Depot)

10. The following two drugs were approved and made available as topical treatment for pain:

- a. Diclofenac epolamine topical patch 1.3% (Flector) and Diclofenac sodium (Voltaren gel 1%)
- b. Diclofenac epolamine topical patch 1.3% (Flector) and Doripenem (Doribox)
- c. Diclofenac sodium (Voltaren gel 1%) and Doripenem (Doribox)
- d. Only Diclofenac sodium (Voltaren gel 1%)

Pre-test Drugs of 2007 and 2008 Con't

11. This drug prevents the HIV virus from entering uninfected cells.
  - a. Maraviroc (Selzentry)
  - b. Methoxy Polyethylene Glycol-Epoetin Beta (Micera)
  - c. Methylnaltrexone bromide (Relistor)
  - d. Paliperidone (Invega)
  
12. The drug Rotigotine (Neupro) is prescribed for:
  - a. Parkinson's disease
  - b. Delivered via a transdermal patch
  - c. a and b
  - d. neither a nor b
  
13. This drug is first in its class as a pleuromutilin antibacterial agent.
  - a. Retapamulin ointment (Altabax)
  - b. Paliperidone (Invega)
  - c. Nebivolol (Bystolic)
  - d. Temsirolimus (Torisel)
  
14. The future of pharmaceutical development includes:
  - a. Developing drugs that are specific for the disease and genetic make-up of individuals.
  - b. Tailoring drugs to help earlier in the disease process rather than later.
  - c. a only
  - d. a and b
  
15. Which of the following drug(s) is approved for the treatment of osteoporosis in postmenopausal women and Paget's disease?
  - a. Temsirolimus (Torisel)
  - b. Zoledronic acid (Reclast)
  - c. Sapropterin (Kuvan)
  - d. Silodosin (Rapaflo)

Excellence in Care: New Drugs Released in 2007 and 2008  
Program Outline

**Written:**

I. Pre-Test

**DVD Presentation:**

II. Introduction to Drugs Released in 2007 and 2008

- A. Pace of release of new drugs in 2007 and 2008
- B. Classifications of new drugs released in 2007 and 2008
- C. Black Box Warnings

III. New Drugs Released in 2007 and 2008- The following drugs are individually discussed on the DVD. Each drug is presented and includes classification, mechanism of action, indication, dosing/administration, and special considerations:

- Aliskiren (Tekturna)
- Alvimopan (Entereg)
- Ambrisentan (Letairis)
- Arformoterol (Brovana)
- Armodafinil (Nuvigil)
- Desvenlafaxine (Pristiq)
- Diclofenac epolamine topical patch 1.3% (Flector)
- Diclofenac sodium (Voltaren gel 1%)
- Doripenem (Doribax)
- Eculizumab (Soliris)
- Ixabepilone (Ixempra)
- Lacosamide (Vimpat)
- Lanreotide (Somatuline Depot)
- Lapatinib (Tykerb)
- Levocetirizine (Xyzal)
- Lisdexamfetamine (Vynase)
- Lubiprostone (Amitiza)
- Maraviroc (Selzentry)
- Methylnaltrexone bromide (Relistor)
- Nebivolol (Bystolic)
- Nilotinib (Tasigna)
- Paliperidone (Invega)
- Raltegravir (Isentress)
- Retapamulin ointment (Altabax)
- Rotigotine (Neupro)
- Sapropterin (Kuvan)

IV. Cellular Markers

- A. Future of Pharmaceutical Development
- B. Definition- what they are

V. Summary

- A. Healthcare professional's responsibility to stay current
- B. Know where to find information

**Written:**

VI. Post-Test

VII. Evaluation

# Evaluation

**Title of Education Activity:** Excellence in Care: New Drugs Released in 2007 and 2008

**Location:** DVD Video Format

**Date:** Participants check out and complete on own time

**Purpose of this activity:** The purpose of this activity is to enrich the participant's contribution to quality healthcare and the pursuit of professional career goals by providing updated information on the use, interaction concerns, and precautions needed regarding new medications approved by the FDA and released in 2007 and 2008.

**Directions/Instructions:** Please complete this evaluation questionnaire. Your anonymous responses will be used to revise this activity and to plan future educational activities. Circle the number that best fits your evaluation of this activity.

1 = Not at all      2 = Somewhat      3 = Almost completely      4 = Completely

## 1. Rate your achievement of these objectives:

- |   |   |   |   |   |
|---|---|---|---|---|
| a. Identify two (2) classifications in which the new drugs released in 2007 and 2008 address.   | 1 | 2 | 3 | 4 |
| b. Identify the required warning (by the FDA) to be placed on pharmaceutical labels when there is something important or outstanding about a medication (particularly a side effect). | 1 | 2 | 3 | 4 |
| c. List two (2) new topical drugs available for the treatment of pain.  | 1 | 2 | 3 | 4 |
| d. Describe three (3) new drugs released in 2007 and 2008 including their mechanism of action, route of administration, and any special considerations.                               | 1 | 2 | 3 | 4 |
| e. Discuss the future of pharmaceutical development and its relationship to cellular markers.   | 1 | 2 | 3 | 4 |
| f. Discuss the healthcare professionals responsibility in staying current with new pharmaceuticals released each year.  | 1 | 2 | 3 | 4 |

## 2. Rate the effectiveness of the teaching/learning resources?

## 3. Please evaluate the guest speaker- Renee Acosta, RPh

- |   |   |   |   |   |
|---|---|---|---|---|
| a. Knowledge and currency of topic      | 1 | 2 | 3 | 4 |
| b. Ability to make points clear         | 1 | 2 | 3 | 4 |
| c. Ability to apply content to practice | 1 | 2 | 3 | 4 |

**4. Please evaluate the moderator- Elizabeth Huss RN, BSN**

- |   |   |   |   |   |
|---|---|---|---|---|
| a. Guides the discussion                          | 1 | 2 | 3 | 4 |
| b. Asks pertinent questions                       | 1 | 2 | 3 | 4 |
| c. Fosters clarification of presented information | 1 | 2 | 3 | 4 |

**5. Were the objectives relevant to the overall purpose?** 1 2 3 4  
(see above)

**5. How long (in minutes) did it take you to complete the entire activity (including taking the pre-test, watching the video, taking the post-test, and completing this evaluation tool)? \_\_\_\_\_**  
**Minutes**

**6. List two (2) ways you will integrate what you learned in this activity into your practice and/or employment environment.**

**8. The following were disclosed prior to the beginning of this activity either in writing or verbally?**

- |   |     |    |
|---|-----|----|
| a. Requirements for successful completion | Yes | No |
| b. Conflicts of Interest                  | Yes | No |
| c. Commercial Support                     | Yes | No |
| d. Non-endorsement of Products            | Yes | No |
| e. Off-label Use                          | Yes | No |

**9. Did you, as a participant, notice any bias that was not previously disclosed in this presentation?** Yes No

**If “Yes”, please describe who was biased and how.**

**10. Comments:** If you answered (1) to any of the above, please comment.

**11. Please list any suggestions or topics for future programming.**

**Print Name:**

**Date:**

**Instructions:** Choose the best answer for each question listed below and circle the corresponding letter. A passing score of 80% (answer 12 or more correctly) or more is required to earn continuing nursing education (CNE). After you have completed this post-test, submit it along with your completed evaluation, pre-test, registration form and payment to:

**Austin Community College  
Health Professions Institute  
Attn: Online Nursing Videos  
5930 Middle Fiskville Rd.  
Austin, TX 78752  
Fax: 512-223-7030**

**Post-Test: New Drugs Released in 2007 and 2008**

1. Healthcare professionals have a responsibility to:
  - a. Stay current with regard to new drugs approved each year
  - b. Learn about those drugs they frequently work with
  - c. Know where to find information pertaining to drugs and drug therapy
  - d. All of the above
  
2. All of the following are true about Aliskiren (Tekturna) EXCEPT:
  - a. It is indicated for the treatment of hypertension
  - b. Dosing is usually 150 mg daily
  - c. Must be given consistently with regard to meals
  - d. Must be given without food
  
3. When there is something important about a medication (particularly a side effect), the FDA requires a warning on the label up-front. What is this warning called?
  - a. Black box warning
  - b. WARNING:
  - c. CAUTION:
  - d. Red Alert
  
4. Which of the following drug(s) has a pending FDA approval for the treatment of vasomotor symptoms associated with menopause?
  - a. Arformoterol (Brovana)
  - b. Desvenlafaxine (Pristiq)
  - c. Ambrisentan (Letairis)
  - d. Diclofenac epolamine topical patch 1.3% (Flector)

Post-Test: New Drugs Released in 2007 and 2008 Con't

5. This antimicrobial / bactericidal IV medication used to treat severe infections requires adjusting the dosage for the creatinine clearance.

- a. Doripenem (Doribox)
- b. Eculizumab (Soliris)
- c. Diclofenac epolamine topical patch 1.3% (Flector)
- d. Diclofenac sodium (Voltaren gel 1%)

6. All of the following are true concerning the drug Eculizumab (Soliris) EXCEPT:

- a. It decreases the destruction of red blood cells
- b. It is administered IV
- c. It is the first drug approved for PNH (paroxysmal nocturnal hemoglobinuria)
- d. It is given orally

7. Of the following drug(s), which comes with a recommendation for the meningococcal vaccine at least 2 weeks prior to receiving the first dose because of an increased risk for meningococcal infections?

- a. Fesoterodine (Toviaz)
- b. Ixabepilone (Ixempra)
- c. Eculizumab (Soliris)
- d. Methylnaltrexone bromide (Relistor)

8. Which of the following drug(s) is administered via deep subcutaneous injection and is given for the long-term treatment of acromegalic clients?

- a. Lapatinib (Tykerb)
- b. Levocetirizine (Xyzal)
- c. Lubiprostone (Amitiza)
- d. Lanreotide (Somatuline Depot)

9. Which of the following drug(s) is given for advanced or metastatic breast cancer tumors that over-express HER2 and in combination with capecitabine?

- a. Lapatinib (Tykerb)
- b. Levocetirizine (Xyzal)
- c. Lubiprostone (Amitiza)
- d. Lanreotide (Somatuline Depot)

10. The following two drugs were approved and made available as topical treatment for pain:

- a. Diclofenac epolamine topical patch 1.3% (Flector) and Diclofenac sodium (Voltaren gel 1%)
- b. Diclofenac epolamine topical patch 1.3% (Flector) and Doripenem (Doribax)
- c. Diclofenac sodium (Voltaren gel 1%) and Doripenem (Doribax)
- d. Only Diclofenac sodium (Voltaren gel 1%)

Post-Test: New Drugs Released in 2007 and 2008 Con't

11. This drug prevents the HIV virus from entering uninfected cells.
  - a. Maraviroc (Selzentry)
  - b. Methoxy Polyethylene Glycol-Epoetin Beta (Micera)
  - c. Methylnaltrexone bromide (Relistor)
  - d. Paliperidone (Invega)
  
12. The drug Rotigotine (Neupro) is prescribed for:
  - a. Parkinson's disease
  - b. Delivered via a transdermal patch
  - c. a and b
  - d. neither a nor b
  
13. This drug is first in its class as a pleuromutilin antibacterial agent.
  - a. Retapamulin ointment (Altabax)
  - b. Paliperidone (Invega)
  - c. Nebivolol (Bystolic)
  - d. Temsirolimus (Torisel)
  
14. The future of pharmaceutical development includes:
  - a. Developing drugs that are specific for the disease and genetic make-up of individuals.
  - b. Tailoring drugs to help earlier in the disease process rather than later.
  - c. a only
  - d. a and b
  
15. Which of the following drug(s) is approved for the treatment of osteoporosis in postmenopausal women and Paget's disease?
  - a. Temsirolimus (Torisel)
  - b. Zoledronic acid (Reclast)
  - c. Sapropterin (Kuvan)
  - d. Silodosin (Rapaflo)